Cargando…

EGFR-targeted mAb therapy modulates autophagy in head and neck squamous cell carcinoma through NLRX1-TUFM protein complex

EGFR-targeted therapy in head and neck squamous cell carcinoma (HNSCC) patients frequently results in tumor resistance to treatment. Autophagy is an emerging underlying resistance mechanism, however, the molecular autophagy machinery in HNSCC cells and potential biomarkers of patient response to EGF...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lei, Yu, Kansy, Benjamin A., Li, Jing, Cong, Linhai, Liu, Yang, Trivedi, Sumita, Wen, Haitao, Ting, Jenny P.-Y., Ouyang, Hongjiao, Ferris, Robert L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5257174/ https://www.ncbi.nlm.nih.gov/pubmed/26876213 http://dx.doi.org/10.1038/onc.2016.11

Ejemplares similares

Anti-EGFR mAb cetuximab therapy increases T cell receptor (TCR) diversity in the peripheral blood and focuses TCR richness in the tumor microenvironment
por: Kansy, Benjamin A, et al.
Publicado: (2015)

Activation of mitochondrial TUFM ameliorates metabolic dysregulation through coordinating autophagy induction
por: Kim, Dasol, et al.
Publicado: (2021)

STAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients
por: Srivastava, Raghvendra M, et al.
Publicado: (2013)

Are Mutations of the EGFR Gene Promising Predictive Markers for Anti-EGFR mAbs in Colorectal Carcinomas?
por: Park, Dong-Guk
Publicado: (2011)

Autophagy-competent mitochondrial translation elongation factor TUFM inhibits caspase-8-mediated apoptosis
por: Choi, Chang-Yong, et al.
Publicado: (2021)

SEPPA-mAb: spatial epitope prediction of protein antigens for mAbs
por: Qiu, Tianyi, et al.
Publicado: (2023)

Inhibition of Avian Influenza A Virus Replication in Human Cells by Host Restriction Factor TUFM Is Correlated with Autophagy
por: Kuo, Shu-Ming, et al.
Publicado: (2017)

Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs
por: Fusco, Marnie L., et al.
Publicado: (2015)

The Different Colors of mAbs in Solution
por: Ambrogelly, Alexandre
Publicado: (2021)

TUFM-knockdown inhibits the migration and proliferation of gastrointestinal stromal tumor cells
por: Weng, Xiaoyuan, et al.
Publicado: (2020)

Correction: Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs
por: Fusco, Marnie L., et al.
Publicado: (2015)

Metformin Enhances the Therapy Effects of Anti-IGF-1R mAb Figitumumab to NSCLC
por: Cao, Hongxin, et al.
Publicado: (2016)

Down-regulation of TUFM impairs host cell interaction and virulence by Paracoccidioides brasiliensis
por: Marcos, Caroline Maria, et al.
Publicado: (2019)

Anti-EGFR targeted monoclonal antibody isotype influences anti-tumor immunity in head and neck cancer patients
por: Trivedi, Sumita, et al.
Publicado: (2015)

Cellular tools for biosimilar mAb analysis
por: Lindemann, Carsten, et al.
Publicado: (2013)

Evolving trends in mAb production processes
por: Shukla, Abhinav A., et al.
Publicado: (2017)

State of the art in anti-cancer mAbs
por: Chiavenna, S. M., et al.
Publicado: (2017)

NLRX1 negatively modulates type I IFN to facilitate KSHV reactivation from latency
por: Ma, Zhe, et al.
Publicado: (2017)

Optimizing sequential treatment with anti-EGFR and VEGF mAb in metastatic colorectal cancer: current results and controversies
por: Chen, Datian, et al.
Publicado: (2019)

Silencing TUFM Inhibits Development of Monocrotaline-Induced Pulmonary Hypertension by Regulating Mitochondrial Autophagy via AMPK/mTOR Signal Pathway
por: Wei, Ruyuan, et al.
Publicado: (2022)

Nlrx1 regulates neuronal cell death
por: Imbeault, Emilie, et al.
Publicado: (2014)

Glioblastoma-specific anti-TUFM nanobody for in-vitro immunoimaging and cancer stem cell targeting
por: Samec, Neja, et al.
Publicado: (2018)

mAb MDR1-modified chitosan nanoparticles overcome acquired EGFR-TKI resistance through two potential therapeutic targets modulation of MDR1 and autophagy
por: Zheng, Yan, et al.
Publicado: (2017)

Stability enhancement in a mAb and Fab coformulation
por: Zhang, Hongyu, et al.
Publicado: (2020)

Pan-sarbecovirus mAb protects from variants
por: Flemming, Alexandra
Publicado: (2021)

A mAb for the detection of the antiretroviral drug emtricitabine
por: Youngpairoj, Ae S., et al.
Publicado: (2022)

Combinational Therapy Enhances the Effects of Anti-IGF-1R mAb Figitumumab to Target Small Cell Lung Cancer
por: Cao, Hongxin, et al.
Publicado: (2015)

Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy
por: Alig, Annabel H. S., et al.
Publicado: (2022)

Expression and clinicopathologic significance of TUFM and p53 for the normal–adenoma–carcinoma sequence in colorectal epithelia
por: Xi, Hong-Qing, et al.
Publicado: (2017)

Modeling-Enabled Characterization of Novel NLRX1 Ligands
por: Lu, Pinyi, et al.
Publicado: (2015)

NLRX1 Regulation Following Acute Mitochondrial Injury
por: Chu, Xiaogang, et al.
Publicado: (2019)

Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy
por: Oppenheim, D E, et al.
Publicado: (2014)

Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10
por: Modjtahedi, H, et al.
Publicado: (2012)

Novel strategy for a high-yielding mAb-producing CHO strain (overexpression of non-coding RNA enhanced proliferation and improved mAb yield)
por: Tabuchi, Hisahiro
Publicado: (2013)

Dual “mAb” HER family blockade in head and neck cancer human cell lines combined with photon therapy
por: Guy, Jean-Baptiste, et al.
Publicado: (2017)

Synergistic potentiation of the anti-metastatic effect of anti EGFR mAb by its combination with immunotherapies targeting the ganglioside NGcGM3
por: Palomo, Addys González, et al.
Publicado: (2018)

A Novel Anti-EGFR mAb Ame55 with Lower Toxicity and Better Efficacy than Cetuximab When Combined with Irinotecan
por: Qiu, Weiyi, et al.
Publicado: (2019)

Focusing on the Cell Type Specific Regulatory Actions of NLRX1
por: Fekete, Tünde, et al.
Publicado: (2021)

Anti-PD-1 mAb pre-radiotherapy (RT) loading dose and fractionated RT induce better tumor-specific immunity and tumor shrinkage than sequential administration in an HPV+ head and neck cancer model
por: Srivastava, Raghvendra M, et al.
Publicado: (2015)

NLRX1 Negatively Regulates Group A Streptococcus Invasion and Autophagy Induction by Interacting With the Beclin 1–UVRAG Complex
por: Aikawa, Chihiro, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tq3b6rnc7kgl3rl617teli8klu